Navigation Links
FDA Approves First of Its Kind, Fully Implantable (Surgically), Invisible, Prosthetic Hearing Restoration Device
Date:3/17/2010

MINNEAPOLIS, March 17 /PRNewswire/ -- On March 17, 2010 the FDA gave approval to Envoy Medical Corporation to market a "First of its Kind" prosthetic hearing restoration device. The approval follows a December 18, 2009 unanimous 15 to 0 vote by an independent advisory panel in favor of approving the Esteem® for moderate to severe sensorineural hearing loss. The FDA chose an expedited review process, noting that they believe the Esteem® "represents a breakthrough technology."

In clinical trials, the Esteem® averaged a statistically significant increase in gain above hearing aids for Speech Reception Threshold (SRT) and Word Recognition Scores (WRS). Patrick Spearman, CEO of Envoy Medical, was quoted as saying: "This is huge. It means that sufferers of sensorineural hearing loss [approx. 90% of hearing loss sufferers] can now have a chance to hear much better than with conventional hearing aid technology."

Unlike hearing aids, the Esteem® does not use a microphone or a speaker. Instead, it uses the natural ear drum to detect sounds and sends a clear message to the brain, via the auditory nerve, by stimulating the cochlea with its prosthetic stimulator. Shelly Amann, President of Envoy Medical, noted: "Once implanted, Esteem® is invisible, not just to others, but the patient is also unaware of its presence in their body. Recipients can resume a normal life."

The direct cost to the recipient for the device and implant surgery is approximately $30,000. The company says that financing options are available, making it affordable to hundreds of thousands of sufferers. The pacemaker-type battery may last up to nine years and never needs to be recharged.

Further information can be found on Envoy Medical's web site www.envoymedical.com or by calling toll free 866-950-HEAR (4327).

SOURCE Envoy Medical Corporation

Back to top

RELATED LINKS
http://www.envoymedical.com

'/>"/>

SOURCE Envoy Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves First Totally Implanted Hearing System
2. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
3. FDA Approves Name Change for Heartburn Drug Kapidex
4. FDA Approves First Generic Tamsulosin to Treat Enlarged Prostate Gland
5. FDA Approves First New Inhaled Antibiotic for CF in More Than a Decade
6. FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinsons Disease
7. FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
8. FDA Approves Xiaflex for Debilitating Hand Condition
9. FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures
10. Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril
11. FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
(Date:4/28/2016)... April 28, 2016 , Net Sales of ... basis over the prior year period, and an increase of ... , Diluted EPS for the first quarter were $0.52 reported, ... $2.00 adjusted, an increase of 29.9% over the prior year ... adjusted earnings guidance for 2016 Zimmer Biomet Holdings, ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Celiac Association (CCA), is pleased to announce the launch of the GFCP ... articles, recipes, and more. The purpose of the GFCP Scoop site ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE ... entirely on patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower ... 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses who have ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... to promote their animal line of probiotics, Petbiotics ™, as they fondly ... turnout of animal rescue groups networking for their non-profit organizations. Animal rescues across ...
Breaking Medicine News(10 mins):